Rafferty Asset Management LLC acquired a new position in shares of BioAtla, Inc. (NASDAQ:BCAB) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 25,458 shares of the company’s stock, valued at approximately $1,079,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of BioAtla by 558.8% in the first quarter. BlackRock Inc. now owns 967,371 shares of the company’s stock worth $49,180,000 after acquiring an additional 820,538 shares during the last quarter. Geode Capital Management LLC increased its stake in BioAtla by 1,017.9% in the first quarter. Geode Capital Management LLC now owns 194,952 shares of the company’s stock valued at $9,911,000 after purchasing an additional 177,513 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in BioAtla during the first quarter valued at about $6,781,000. Northern Trust Corp purchased a new stake in BioAtla during the first quarter valued at about $6,240,000. Finally, JPMorgan Chase & Co. grew its position in BioAtla by 7,262.7% during the first quarter. JPMorgan Chase & Co. now owns 80,106 shares of the company’s stock valued at $4,072,000 after acquiring an additional 79,018 shares during the period. 62.62% of the stock is owned by institutional investors.
In related news, Director Guy Levy sold 546,709 shares of the stock in a transaction that occurred on Tuesday, August 24th. The stock was sold at an average price of $39.65, for a total value of $21,677,011.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jay M. Phd Short sold 4,533 shares of the stock in a transaction that occurred on Tuesday, August 24th. The stock was sold at an average price of $41.60, for a total value of $188,572.80. Following the completion of the transaction, the chief executive officer now directly owns 1,441,508 shares of the company’s stock, valued at $59,966,732.80. The disclosure for this sale can be found here. Insiders have sold 592,719 shares of company stock worth $23,525,231 in the last 90 days. 35.50% of the stock is currently owned by insiders.
NASDAQ:BCAB opened at $32.26 on Tuesday. BioAtla, Inc. has a one year low of $27.15 and a one year high of $76.63. The business’s 50-day simple moving average is $39.84 and its 200 day simple moving average is $45.26.
BioAtla (NASDAQ:BCAB) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by ($0.34). As a group, equities research analysts predict that BioAtla, Inc. will post -3.22 earnings per share for the current year.
BioAtla Company Profile
BioAtla, Inc, a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types.
Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB).
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.